Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

A fusion-loop antibody enhances the infectious properties of immature flavivirus particles.

Rodenhuis-Zybert IA, Moesker B, da Silva Voorham JM, van der Ende-Metselaar H, Diamond MS, Wilschut J, Smit JM.

J Virol. 2011 Nov;85(22):11800-8. doi: 10.1128/JVI.05237-11. Epub 2011 Aug 31.

2.

Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2.

da Silva Voorham JM, Rodenhuis-Zybert IA, Ayala Nuñez NV, Colpitts TM, van der Ende-Metselaar H, Fikrig E, Diamond MS, Wilschut J, Smit JM.

PLoS One. 2012;7(3):e29957. doi: 10.1371/journal.pone.0029957. Epub 2012 Mar 14.

3.

prM-antibody renders immature West Nile virus infectious in vivo.

Colpitts TM, Rodenhuis-Zybert I, Moesker B, Wang P, Fikrig E, Smit JM.

J Gen Virol. 2011 Oct;92(Pt 10):2281-5. doi: 10.1099/vir.0.031427-0. Epub 2011 Jun 22.

4.

Functional importance of dengue virus maturation: infectious properties of immature virions.

Zybert IA, van der Ende-Metselaar H, Wilschut J, Smit JM.

J Gen Virol. 2008 Dec;89(Pt 12):3047-51. doi: 10.1099/vir.0.2008/002535-0.

PMID:
19008392
5.

The infectivity of prM-containing partially mature West Nile virus does not require the activity of cellular furin-like proteases.

Mukherjee S, Lin TY, Dowd KA, Manhart CJ, Pierson TC.

J Virol. 2011 Nov;85(22):12067-72. doi: 10.1128/JVI.05559-11. Epub 2011 Aug 31.

6.

A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus.

Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC.

PLoS Pathog. 2011 Jun;7(6):e1002111. doi: 10.1371/journal.ppat.1002111. Epub 2011 Jun 30.

7.

Immature dengue virus: a veiled pathogen?

Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der Ende-Metselaar H, Lei HY, Wilschut J, Smit JM.

PLoS Pathog. 2010 Jan;6(1):e1000718. doi: 10.1371/journal.ppat.1000718. Epub 2010 Jan 8.

8.

Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody.

Cherrier MV, Kaufmann B, Nybakken GE, Lok SM, Warren JT, Chen BR, Nelson CA, Kostyuchenko VA, Holdaway HA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG, Fremont DH.

EMBO J. 2009 Oct 21;28(20):3269-76. doi: 10.1038/emboj.2009.245. Epub 2009 Aug 27.

9.

Anti-Idiotypic Antibodies Specific to prM Monoantibody Prevent Antibody Dependent Enhancement of Dengue Virus Infection.

Wang M, Yang F, Huang D, Huang Y, Zhang X, Wang C, Zhang S, Zhang R.

Front Cell Infect Microbiol. 2017 May 9;7:157. doi: 10.3389/fcimb.2017.00157. eCollection 2017.

10.

Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus.

Elshuber S, Allison SL, Heinz FX, Mandl CW.

J Gen Virol. 2003 Jan;84(Pt 1):183-91.

PMID:
12533715
11.

Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization.

Nelson S, Jost CA, Xu Q, Ess J, Martin JE, Oliphant T, Whitehead SS, Durbin AP, Graham BS, Diamond MS, Pierson TC.

PLoS Pathog. 2008 May 9;4(5):e1000060. doi: 10.1371/journal.ppat.1000060.

12.

Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.

Keelapang P, Nitatpattana N, Suphatrakul A, Punyahathaikul S, Sriburi R, Pulmanausahakul R, Pichyangkul S, Malasit P, Yoksan S, Sittisombut N.

Vaccine. 2013 Oct 17;31(44):5134-40. doi: 10.1016/j.vaccine.2013.08.027. Epub 2013 Aug 22.

PMID:
23973247
13.

Generation and characterization of a monoclonal antibody against prM protein of West Nile virus.

Guo LP, Huo H, Wang XL, Bu ZG, Hua RH.

Monoclon Antib Immunodiagn Immunother. 2014 Dec;33(6):438-43. doi: 10.1089/mab.2014.0047.

14.

Differential modulation of prM cleavage, extracellular particle distribution, and virus infectivity by conserved residues at nonfurin consensus positions of the dengue virus pr-M junction.

Junjhon J, Lausumpao M, Supasa S, Noisakran S, Songjaeng A, Saraithong P, Chaichoun K, Utaipat U, Keelapang P, Kanjanahaluethai A, Puttikhunt C, Kasinrerk W, Malasit P, Sittisombut N.

J Virol. 2008 Nov;82(21):10776-91. doi: 10.1128/JVI.01180-08. Epub 2008 Aug 20.

15.

Enhancing dengue virus maturation using a stable furin over-expressing cell line.

Mukherjee S, Sirohi D, Dowd KA, Chen Z, Diamond MS, Kuhn RJ, Pierson TC.

Virology. 2016 Oct;497:33-40. doi: 10.1016/j.virol.2016.06.022. Epub 2016 Jul 13.

16.

Substitution of the precursor peptide prevents anti-prM antibody-mediated antibody-dependent enhancement of dengue virus infection.

Wang Y, Si LL, Guo XL, Cui GH, Fang DY, Zhou JM, Yan HJ, Jiang LF.

Virus Res. 2017 Feb 2;229:57-64. doi: 10.1016/j.virusres.2016.12.003. Epub 2016 Dec 6.

PMID:
27939945
17.

Highly conserved residues in the helical domain of dengue virus type 1 precursor membrane protein are involved in assembly, precursor membrane (prM) protein cleavage, and entry.

Hsieh SC, Wu YC, Zou G, Nerurkar VR, Shi PY, Wang WK.

J Biol Chem. 2014 Nov 28;289(48):33149-60. doi: 10.1074/jbc.M114.610428. Epub 2014 Oct 17.

18.

A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection.

Pierson TC, Sánchez MD, Puffer BA, Ahmed AA, Geiss BJ, Valentine LE, Altamura LA, Diamond MS, Doms RW.

Virology. 2006 Mar 1;346(1):53-65. Epub 2005 Dec 2.

19.

The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states.

Lee PD, Mukherjee S, Edeling MA, Dowd KA, Austin SK, Manhart CJ, Diamond MS, Fremont DH, Pierson TC.

J Virol. 2013 Dec;87(24):13729-40. doi: 10.1128/JVI.02340-13. Epub 2013 Oct 9.

Supplemental Content

Support Center